Literature DB >> 21788471

In vitro and in vivo studies of the utility of dimethyl and diethyl carbaporphyrin ketals in treatment of cutaneous leishmaniasis.

Viviana M Taylor1, David L Cedeño, Diana L Muñoz, Marjorie A Jones, Timothy D Lash, Alexandra M Young, Manuel H Constantino, Nicholas Esposito, Iván D Vélez, Sara M Robledo.   

Abstract

Carbaporphyrin ketals are porphyrinoid compounds in which a pyrrole ring of a typical porphyrin macrocycle has been replaced by a ketal-substituted indene ring. It was recently demonstrated that these compounds are effective in vitro against Leishmania tarentolae. Their in vitro effectiveness is increased when they are exposed to visible light; they act as photosensitizers capable of mediating the production of reactive oxygen species (ROS). Following on this evidence, the effectiveness and cytotoxicity of the dimethyl and diethyl carbaporphyrin ketals (CKOMe and CKOEt, respectively) were determined in vitro using pathogenic Leishmania species with and without exposure to visible light (2 and 4 h). The effectiveness against various pathogenic Leishmania species was determined to be in a micromolar range. Additionally, the effect of encapsulating the carbaporphyrin ketals in liposome formulations was tested. Liposomal delivery diminished their toxicity, while the effectiveness was enhanced upon exposure to visible light (photodynamic effect). The cytotoxicity levels for human U937 cells and hamster peritoneal macrophages were in the ranges of 0.3 to 9 μM and 7 to 330 μM, respectively. When tested in vivo, using a hamster (Mesocricetus auratus) model of cutaneous leishmaniasis, CKOMe was active even in the dark, suggesting that the compound, once metabolized in the animal tissue, produces an active ingredient that does not seem to be photosensitive. Reduction in lesion size, histopathologic analyses, and smears confirmed the in vivo effectiveness of the compound, since the parasitic load was diminished without noticeable toxic effects.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21788471      PMCID: PMC3186979          DOI: 10.1128/AAC.00671-11

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  41 in total

1.  Liposomal zinc phthalocyanine as a potential agent for photodynamic therapy of leishmaniasis.

Authors:  Ameneh Sazgarnia; Mohammad Hossein Bahreyni-Toosi; Pouran Layegh; Omid Rajabi; Rahman Movahhed Ghodsinia
Journal:  Indian J Dermatol Venereol Leprol       Date:  2010 Jul-Aug       Impact factor: 2.545

2.  Photosensitizers in clinical PDT.

Authors:  Ron R Allison; Gordon H Downie; Rosa Cuenca; Xin-Hua Hu; Carter Jh Childs; Claudio H Sibata
Journal:  Photodiagnosis Photodyn Ther       Date:  2004-05       Impact factor: 3.631

Review 3.  Treatment of New World cutaneous leishmaniasis with miltefosine.

Authors:  J Soto; J Berman
Journal:  Trans R Soc Trop Med Hyg       Date:  2006-08-22       Impact factor: 2.184

4.  Photodynamic sensitization of Leishmania amazonensis in both extracellular and intracellular stages with aluminum phthalocyanine chloride for photolysis in vitro.

Authors:  Sujoy Dutta; Debalina Ray; Bala K Kolli; Kwang-Poo Chang
Journal:  Antimicrob Agents Chemother       Date:  2005-11       Impact factor: 5.191

5.  [Efficacy and toxicity of pentavalent antimonials (Glucantime and Pentostam) in an American cutaneous leishmaniasis animal model: luminometry application].

Authors:  Hector Hernán Henao; Yaneth Osorio; Nancy Gore Saravia; Arlen Gómez; Bruno Travi
Journal:  Biomedica       Date:  2004-12       Impact factor: 0.935

6.  Genetic rescue of Leishmania deficiency in porphyrin biosynthesis creates mutants suitable for analysis of cellular events in uroporphyria and for photodynamic therapy.

Authors:  Jerome Franklin Sah; Hiroya Ito; Bala Krishna Kolli; Daniel A Peterson; Shigeru Sassa; Kwang-Poo Chang
Journal:  J Biol Chem       Date:  2002-02-08       Impact factor: 5.157

7.  Histopathological studies of visceralized Leishmania (Leishmania) amazonensis in mice experimentally infected.

Authors:  A L Abreu-Silva; K S Calabrese; S M N Cupolilo; F O Cardoso; C S F Souza; S C Gonçalves da Costa
Journal:  Vet Parasitol       Date:  2004-05-26       Impact factor: 2.738

8.  Photodynamic therapy for cutaneous leishmaniasis: the effectiveness of topical phenothiaziniums in parasite eradication and Th1 immune response stimulation.

Authors:  Oleg E Akilov; Sachiko Kosaka; Katie O'Riordan; Tayyaba Hasan
Journal:  Photochem Photobiol Sci       Date:  2007-07-19       Impact factor: 3.982

9.  Carbaporphyrin ketals as potential agents for a new photodynamic therapy treatment of leishmaniasis.

Authors:  Justin B Morgenthaler; Steven J Peters; David L Cedeño; Manuel H Constantino; Kevin A Edwards; Erin M Kamowski; Jennifer C Passini; Brian E Butkus; Alexandra M Young; Timothy D Lash; Marjorie A Jones
Journal:  Bioorg Med Chem       Date:  2008-05-20       Impact factor: 3.641

Review 10.  Cutaneous leishmaniasis treatment.

Authors:  Philippe Minodier; Philippe Parola
Journal:  Travel Med Infect Dis       Date:  2006-10-31       Impact factor: 6.211

View more
  13 in total

1.  Repurposing of known drugs for leishmaniasis treatment using bioinformatic predictions, in vitro validations and pharmacokinetic simulations.

Authors:  Christian Bustamante; Rodrigo Ochoa; Claudia Asela; Carlos Muskus
Journal:  J Comput Aided Mol Des       Date:  2019-10-14       Impact factor: 3.686

2.  In vitro evaluation of photodynamic therapy using curcumin on Leishmania major and Leishmania braziliensis.

Authors:  Juliana Guerra Pinto; Letícia Correa Fontana; Marco Antonio de Oliveira; Cristina Kurachi; Leandro José Raniero; Juliana Ferreira-Strixino
Journal:  Lasers Med Sci       Date:  2016-04-07       Impact factor: 3.161

3.  Development of a novel formulation with hypericin to treat cutaneous leishmaniasis based on photodynamic therapy in in vitro and in vivo studies.

Authors:  Andrés Montoya; Alejandro Daza; Diana Muñoz; Karina Ríos; Viviana Taylor; David Cedeño; Iván D Vélez; Fernando Echeverri; Sara M Robledo
Journal:  Antimicrob Agents Chemother       Date:  2015-07-13       Impact factor: 5.191

Review 4.  Phototherapy and optical waveguides for the treatment of infection.

Authors:  Dingbowen Wang; Michelle Laurel Kuzma; Xinyu Tan; Tong-Chuan He; Cheng Dong; Zhiwen Liu; Jian Yang
Journal:  Adv Drug Deliv Rev       Date:  2021-11-03       Impact factor: 15.470

Review 5.  Liposomal drug delivery systems for the treatment of leishmaniasis.

Authors:  Felipe Francisco Tuon; Leticia Ramos Dantas; Regina Maia de Souza; Victoria Stadler Tasca Ribeiro; Valdir Sabbaga Amato
Journal:  Parasitol Res       Date:  2022-09-16       Impact factor: 2.383

Review 6.  Light based anti-infectives: ultraviolet C irradiation, photodynamic therapy, blue light, and beyond.

Authors:  Rui Yin; Tianhong Dai; Pinar Avci; Ana Elisa Serafim Jorge; Wanessa C M A de Melo; Daniela Vecchio; Ying-Ying Huang; Asheesh Gupta; Michael R Hamblin
Journal:  Curr Opin Pharmacol       Date:  2013-09-20       Impact factor: 5.547

7.  Enhanced photodynamic leishmanicidal activity of hydrophobic zinc phthalocyanine within archaeolipids containing liposomes.

Authors:  Ana Paula Perez; Agustina Casasco; Priscila Schilrreff; Maria Victoria Defain Tesoriero; Luc Duempelmann; Juan Sebastián Pappalardo; Maria Julia Altube; Leticia Higa; Maria Jose Morilla; Patricia Petray; Eder L Romero
Journal:  Int J Nanomedicine       Date:  2014-07-10

8.  Hydrazone Derivatives Enhance Antileishmanial Activity of Thiochroman-4-ones.

Authors:  Esteban Vargas; Fernando Echeverri; Yulieth A Upegui; Sara M Robledo; Wiston Quiñones
Journal:  Molecules       Date:  2017-12-29       Impact factor: 4.411

Review 9.  Pheophorbide a: State of the Art.

Authors:  Assunta Saide; Chiara Lauritano; Adrianna Ianora
Journal:  Mar Drugs       Date:  2020-05-14       Impact factor: 5.118

10.  Alkyl and Aryl Derivatives Based on p-Coumaric Acid Modification and Inhibitory Action against Leishmania braziliensis and Plasmodium falciparum.

Authors:  Susiany P Lopes; Lina M Yepes; Yunierkis Pérez-Castillo; Sara M Robledo; Damião P de Sousa
Journal:  Molecules       Date:  2020-07-11       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.